Latest Neurizon Therapeutics News & Updates

See the latest news and media coverage for Neurizon Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Neurizon Therapeutics

Biotechnology company developing neurodegenerative disease treatments

neurizon.com
Headquarters
Melbourne, Australia
Company type
Public company
Number of employees
2–15

Latest news about Neurizon Therapeutics

Company announcements

  • Neurizon Therapeutics

    Neurizon Therapeutics announces new preclinical data on NUZ-001

    NUZ-001 increases activity in protein clearance pathways like autophagy and proteasomal system in neuronal models. Findings support its profile for ALS treatment in HEALEY trial.

  • Neurizon Therapeutics

    Neurizon Therapeutics doses first participant with NUZ-001

    This occurs in Regimen I of the HEALEY ALS Platform Trial, a Phase 2/3 study evaluating NUZ-001 in 160 participants across US ALS centers.

  • Neurizon Therapeutics

    Neurizon secures $6 million R&D tax rebate

    The rebate reflects 48.5% on eligible FY2025 activities. Net cash of $4.35 million received after loan repayment. Funds support HEALEY ALS Platform Trial.

  • Neurizon Therapeutics

    Neurizon completes entitlement offer

    The announcement was released on 26 Jan 2026.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Neurizon Therapeutics

Track Neurizon Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Neurizon Therapeutics competitors & trending companies

Browse news for competitors to Neurizon Therapeutics and other trending companies.